Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.
Virological failure on a boosted-protease inhibitor (PI/r) first-line triple combination is usually not associated with the detection of resistance mutations in the protease gene. Thus, other resistance pathways are being investigated. First-line PI/r monotherapy is the best model to investigate in...
Main Authors: | Jade Ghosn, Constance Delaugerre, Philippe Flandre, Julie Galimand, Isabelle Cohen-Codar, François Raffi, Jean-François Delfraissy, Christine Rouzioux, Marie-Laure Chaix |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3176769?pdf=render |
Similar Items
-
Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
by: Farinotti Robert, et al.
Published: (2010-05-01) -
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
by: Nicola Gianotti, et al.
Published: (2017-01-01) -
Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.
by: José R Santos, et al.
Published: (2013-01-01) -
Recurrent oedema associated with the co-formulation of lopinavir and ritonavir Edema recorrente associado à co-formulação de lopinavir e ritonavir
by: Jorge Francisco C. Pinto, et al.
Published: (2004-08-01) -
Toxicity for warfarine switching from lopinavir/ritonavir to dolutegravir
by: Ana Pelufo-Pellicer, et al.
Published: (2017-03-01)